{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:45:51Z","timestamp":1791045951290,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T00:00:00Z","timestamp":1245196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s11239-009-0363-x","type":"journal-article","created":{"date-parts":[[2009,6,16]],"date-time":"2009-06-16T09:57:00Z","timestamp":1245146220000},"page":"489-495","source":"Crossref","is-referenced-by-count":22,"title":["Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS)"],"prefix":"10.1007","volume":"28","author":[{"given":"Felicita","family":"Andreotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Agati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Santucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Mattatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Autore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,17]]},"reference":[{"issue":"23","key":"363_CR1","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","volume":"29","author":"F Werf Van de","year":"2008","unstructured":"Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 29(23):2909\u20132945","journal-title":"Eur Heart J"},{"issue":"17","key":"363_CR2","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/jama.297.17.1892","volume":"297","author":"KAA Fox","year":"2007","unstructured":"Fox KAA, Steg GP, Eagle KA et al (2007) Decline in rates of death and heart failure in acute coronary syndromes, 1999\u20132006. JAMA 297(17):1892\u20131900","journal-title":"JAMA"},{"issue":"3","key":"363_CR3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.amjcard.2005.08.053","volume":"97","author":"E Biagini","year":"2006","unstructured":"Biagini E, van Geuns RJ, Baks T et al (2006) Comparison between contrast echocardiography and magnetic resonance imaging to predict improvement of myocardial function after primary coronary intervention. Am J Cardiol 97(3):361\u2013366","journal-title":"Am J Cardiol"},{"key":"363_CR4","doi-asserted-by":"crossref","unstructured":"Takemura G, Nakagawa M, Kanamori H, et al (2009) Benefits of reperfusion beyond infarct size limitation. Cardiovasc Res, Feb 18 (Epub ahead of print)","DOI":"10.1093\/cvr\/cvp032"},{"issue":"5","key":"363_CR5","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1161\/01.CIR.0000115207.45378.BC","volume":"109","author":"F Andreotti","year":"2004","unstructured":"Andreotti F, Crea F, Conti E (2004) Heart-kidney interactions in ischemic syndromes. Circulation 109(5):e31\u2013e32","journal-title":"Circulation"},{"issue":"15","key":"363_CR6","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1161\/01.CIR.0000144309.87183.FB","volume":"110","author":"E Conti","year":"2004","unstructured":"Conti E, Carrozza C, Capoluongo E et al (2004) Insulin-like growth factor-1 as a vascular protective factor. Circulation 110(15):2260\u20132265","journal-title":"Circulation"},{"issue":"4","key":"363_CR7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/187152508785909456","volume":"6","author":"E Conti","year":"2008","unstructured":"Conti E, Musumeci MB, Assenza GE et al (2008) Recombinant human insulin-like growth factor-1: a new cardiovascular disease treatment option? Cardiovasc Hematol Agents Med Chem 6(4):258\u2013271","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"1","key":"363_CR8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jama.293.1.90","volume":"293","author":"K Maiese","year":"2005","unstructured":"Maiese K, Li F, Chong ZZ (2005) New avenues of exploration for erythropoietin. JAMA 293(1):90\u201395","journal-title":"JAMA"},{"issue":"2","key":"363_CR9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cardiores.2004.03.017","volume":"63","author":"MA Bogoyevitch","year":"2004","unstructured":"Bogoyevitch MA (2004) An update on the cardiac effects of erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63(2):208\u2013216","journal-title":"Cardiovasc Res"},{"issue":"17","key":"363_CR10","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1161\/01.CIR.0000127954.98131.23","volume":"109","author":"Z Cai","year":"2004","unstructured":"Cai Z, Semenza GL (2004) Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia\/reperfusion injury. Circulation 109(17):2050\u20132053","journal-title":"Circulation"},{"issue":"7","key":"363_CR11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ejheart.2004.03.012","volume":"6","author":"P Meer van de","year":"2004","unstructured":"van de Meer P, Lipsic E, Henning RH et al (2004) Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Failure 6(7):853\u2013859","journal-title":"Eur J Heart Failure"},{"issue":"4","key":"363_CR12","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2003-01-0223","volume":"102","author":"C Heeschen","year":"2003","unstructured":"Heeschen C, Aicher A, Lehmann R et al (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102(4):1340\u20131346","journal-title":"Blood"},{"key":"363_CR13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1161\/01.RES.0000147315.71699.51","volume":"95","author":"E Messina","year":"2004","unstructured":"Messina E, De Angelis L, Frati G et al (2004) Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 95:852\u2013854","journal-title":"Circ Res"},{"issue":"1","key":"363_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/153537020322800101","volume":"228","author":"JW Fisher","year":"2003","unstructured":"Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med 228(1):1\u201314","journal-title":"Exp Biol Med"},{"issue":"3","key":"363_CR15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11239-008-0212-3","volume":"26","author":"F Marzo","year":"2008","unstructured":"Marzo F, Lavorgna A, Coluzzi G et al (2008) Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 26(3):183\u2013187","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"363_CR16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.tips.2008.02.002","volume":"29","author":"NP Riksen","year":"2008","unstructured":"Riksen NP, Hausenloy DJ, Yellon DM (2008) Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 29(5):258\u2013267","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"363_CR17","doi-asserted-by":"crossref","first-page":"R977","DOI":"10.1152\/ajpregu.00577.2003","volume":"286","author":"J Fandrey","year":"2004","unstructured":"Fandrey J (2004) Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 286(6):R977\u2013R988","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"363_CR18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1172\/JCI18200","volume":"112","author":"CJ Parsa","year":"2003","unstructured":"Parsa CJ, Matsumoto A, Kim J et al (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112(7):999\u20131007","journal-title":"J Clin Invest"},{"issue":"8","key":"363_CR19","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1073\/pnas.0630444100","volume":"100","author":"L Calvillo","year":"2003","unstructured":"Calvillo L, Latini R, Kajstura J et al (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. PNAS 100(8):4802\u20134806","journal-title":"PNAS"},{"issue":"20","key":"363_CR20","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1073\/pnas.1930406100","volume":"100","author":"C Moon","year":"2003","unstructured":"Moon C, Krawczyk M, Ahn D et al (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. PNAS 100(20):11612\u201311617","journal-title":"PNAS"},{"issue":"2","key":"363_CR21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.fjc.0000171751.05446.c5","volume":"46","author":"SL Hale","year":"2005","unstructured":"Hale SL, Sesti C, Kloner RA (2005) Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 46(2):211\u2013215","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"363_CR22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10557-005-3189-6","volume":"19","author":"C Moon","year":"2005","unstructured":"Moon C, Krawczyk M, Ahn D et al (2005) Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drug Ther 19(4):243\u2013250","journal-title":"Cardiovasc Drug Ther"},{"issue":"2","key":"363_CR23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.CIR.0000044914.42696.6A","volume":"107","author":"DM Mancini","year":"2003","unstructured":"Mancini DM, Katz SD, Lang CC et al (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107(2):294\u2013299","journal-title":"Circulation"},{"issue":"7","key":"363_CR24","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","volume":"37","author":"DS Silverberg","year":"2001","unstructured":"Silverberg DS, Wexler D, Sheps D et al (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. JACC 37(7):1775\u20131780","journal-title":"JACC"},{"issue":"7","key":"363_CR25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/dji087","volume":"97","author":"J Bohlius","year":"2005","unstructured":"Bohlius J, Langensiepen S, Schwarzer G et al (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97(7):489\u2013498","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"363_CR26","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1159\/000188803","volume":"72","author":"K Iseki","year":"1996","unstructured":"Iseki K, Nishime K, Uehara H et al (1996) Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 72(1):3036","journal-title":"Nephron"},{"issue":"3","key":"363_CR27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1053\/ajkd.1998.v32.pm9740167","volume":"32","author":"M Wakeen","year":"1998","unstructured":"Wakeen M, Zimmerman SW (1998) Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 32(3):488\u2013493","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"363_CR28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab A, Bolton WK, Browne JK et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339(9):584\u2013590","journal-title":"N Engl J Med"},{"issue":"8","key":"363_CR29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF03402029","volume":"8","author":"H Ehrenreich","year":"2002","unstructured":"Ehrenreich H, Hasselblatt M, Dembowsky C et al (2002) Erythropoietin for acute stroke is both safe and beneficial. Mol Med 8(8):495\u2013505","journal-title":"Mol Med"},{"key":"363_CR30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMoa071533","volume":"357","author":"HL Corwin","year":"2007","unstructured":"Corwin HL, Gettinger A, Fabian TC et al (2007) Efficacy and safety of epoietin alfa in critically ill patients. N Engl J Med 357:965\u2013976","journal-title":"N Engl J Med"},{"issue":"2","key":"363_CR31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10557-006-7680-5","volume":"20","author":"E Lipsic","year":"2006","unstructured":"Lipsic E, van der Meer P, Voors AA et al (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20(2):135\u2013141","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"363_CR32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ahj.2007.12.036","volume":"155","author":"AM Belonje","year":"2008","unstructured":"Belonje AM, Voors AA, van Gilst WH et al (2008) Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 155(5):817\u2013822","journal-title":"Am Heart J"},{"key":"363_CR33","unstructured":"www.ClinicalTrial.gov Identifier: NCT 00378352"},{"key":"363_CR34","doi-asserted-by":"crossref","unstructured":"Ott I, Schulz S, Mehilli J, et al (2009) Prospective, randomized, double-blind, placebo-controlled trial of erythropoietin in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention (REVIVAL-3). Am Coll Cardiol Scientific Sessions 2009, Orlando, Fla ( www.ClinicalTrial.gov Identifier: NCT00390832)","DOI":"10.1161\/CIRCINTERVENTIONS.109.904425"},{"issue":"2","key":"363_CR35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijcard.2007.07.076","volume":"131","author":"A Liem","year":"2009","unstructured":"Liem A, van de Woestijne AP, Bruijns E et al (2009) Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 131(2):285\u2013287","journal-title":"Int J Cardiol"},{"key":"363_CR36","first-page":"S876","volume":"118","author":"F Andreotti","year":"2008","unstructured":"Andreotti F, Autore C, Conti E et al (2008) Safety and feasibility of erythropoietin administration in patients with acute ST-elevation myocardial infarction. Circulation 118:S876\u2013S877","journal-title":"Circulation"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-009-0363-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-009-0363-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-009-0363-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T17:50:48Z","timestamp":1685037048000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-009-0363-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,17]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["363"],"URL":"https:\/\/doi.org\/10.1007\/s11239-009-0363-x","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,17]]}}}